This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durata Therapeutics Closes Public Offering Of Common Stock

CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of $7.00 per share, before underwriting discounts, including 1,072,500 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount.

BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and Jefferies LLC acted as joint book-running managers for the offering, and JMP Securities LLC and RBC Capital Markets, LLC acted as co-managers.

A registration statement relating to the securities sold in this offering was declared effective by the Securities and Exchange Commission on April 11, 2013. Copies of the final prospectus relating to this offering may be obtained by contacting BofA Merrill Lynch by mail at 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by e-mail at dg.prospectus_requests@baml.com; Credit Suisse Securities (USA) LLC by mail at One Madison Avenue, New York, NY 10010, Attn: Prospectus Department, by e-mail at newyork.prospectus@credit-suisse.com, or by telephone at 1-800-221-1037; or Jefferies LLC by mail at 520 Madison Avenue, New York, New York 10022, Attn: Equity Syndicate Prospectus Department, by e-mail at Prospectus_Department@Jefferies.com, or by telephone at 1-877-547-6340.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.

CONTACT: Allison Wey
         Durata Therapeutics, Inc.
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,056.89 -23.25 -0.13%
S&P 500 2,112.20 -5.49 -0.26%
NASDAQ 5,062.7090 -29.3760 -0.58%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs